We partner with exceptional teams in high-growth sectors to build scalable, enduring businesses through targeted and hands-on support. We focus on lower mid-market companies (<$10M EBITDA) in high-growth sub-sectors with strong underlying tailwinds.
Our goal is to build the next generation of middle market champions through strategic buy-and-build initiatives, international and product expansion, and proven value acceleration playbooks.
Investment Focus & ThesisOur team brings a unique blend of scientific, executive, and private equity investment experience—enabling us to identify and help unlock value where others can’t.
With a strong track record, including two successful exits, we know what it takes to drive performance.
Learn MoreThe Kineticos Capital Partners Fund Series targets life sciences companies, targeting EBITDA in the $3–6 million range, with flexibility up to $10 million.
We focus on high-growth areas where our team’s experience and strategic approach can create long-term value.
)
"On numerous occasions the Kineticos team has promptly and diligently conducted market research through KOLs and data driven insights."Arranta Bio | Mark Bamforth | CEO
)
"Frank has only been a positive influence and has made several useful introductions and referrals to us already. Very helpful and on point!"Experic | Dave Wood | Chairman and CEO
){kind=logo}
"The team at Kineticos consists of global leaders in the CGT space, and we are excited to have their support in our expansion, extending our reach from Europe to the US."eXmoor | Angela Osborne | CEO
){kind=logo}
May 15, 2025 – Research Triangle Park, NC – Kincell Bio announced the completion of a $22 million round, led by…
Kincell Bio Welcomes Industry Veteran Mark R. Bamforth as Chief Executive Officer to Drive Business Growth Research Triangle Park,…
Experic, a contract development and manufacturing organization (CDMO) and clinical supply services company serving the biopharmaceutical industry, today announced the…